Bronchoprotection of Salbutamol in Asthma and COPD
Information source: University of Saskatchewan
Information obtained from ClinicalTrials.gov on November 03, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Asthma; COPD
Intervention: salbutamol (Drug)
Phase: N/A
Status: Recruiting
Sponsored by: University of Saskatchewan Official(s) and/or principal investigator(s):
Donald Cockcroft, MD, Principal Investigator, Affiliation: University of Saskatchewan
Overall contact:
Beth Davis, BSc, Phone: 306-966-8290, Email: beth.davis@usask.ca
Summary
This study will investigate potential differences in how two puffs of salbutamol protects
airway smooth muscle from contracting in people with asthma and chronic obstructive pulmonary
disease (COPD).
Clinical Details
Official title: Bronchoprotection of Salbutamol in Asthma and COPD
Study design: Treatment, Randomized, Open Label, Uncontrolled, Parallel Assignment, Efficacy Study
Primary outcome: methacholine PC20 dose shift
Detailed description:
In asthma, the administration (inhalation) of a selective β2 receptor agonist (e. g.
salbutamol), prior to methacholine challenge has been shown to shift the dose response curve
to the right and "bronchoprotect" the airway against airway smooth muscle contraction. The
extent of β2 receptor agonist bronchoprotection in COPD is unknown.
Airway hyperresponsiveness (AHR) to direct acting agents such as histamine and methacholine
is a feature of both asthma and COPD. In asthma, the abnormality leading to AHR is believed
to be due to changes in airway smooth muscle (e. g. hypertrophy, hyperplasia, contractile
apparatus) whereas in COPD the AHR is likely due to structural or geometric changes.
We hypothesize that the bronchoprotection afforded by salbutamol against methacholine
challenge will be greater in asthma than in COPD due to differences in underlying airway
abnormalities.
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- asthma or COPD
Exclusion Criteria:
- asthma and COPD
Locations and Contacts
Beth Davis, BSc, Phone: 306-966-8290, Email: beth.davis@usask.ca
University of Saskatchewan, Saskatoon, Saskatchewan S7N 0W8, Canada; Recruiting
Donald Cockcroft, MD, Principal Investigator
Additional Information
Starting date: February 2007
Ending date: February 2009
Last updated: February 28, 2008
|
